437 related articles for article (PubMed ID: 31172267)
1. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
Liang W; Wang F; Chen Q; Dai J; Escara-Wilke J; Keller ET; Zimmermann J; Hong N; Lu Y; Zhang J
J Cancer Res Clin Oncol; 2019 Aug; 145(8):1999-2012. PubMed ID: 31172267
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis.
Duong LT; Wesolowski GA; Leung P; Oballa R; Pickarski M
Mol Cancer Ther; 2014 Dec; 13(12):2898-909. PubMed ID: 25249554
[TBL] [Abstract][Full Text] [Related]
3. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
[TBL] [Abstract][Full Text] [Related]
4. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
5. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.
Sudhan DR; Pampo C; Rice L; Siemann DW
Int J Cancer; 2016 Jun; 138(11):2665-77. PubMed ID: 26757413
[TBL] [Abstract][Full Text] [Related]
8. Effects of pharmacological inhibition of cathepsin K on fracture repair in mice.
Soung do Y; Gentile MA; Duong LT; Drissi H
Bone; 2013 Jul; 55(1):248-55. PubMed ID: 23486186
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
[TBL] [Abstract][Full Text] [Related]
10. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.
Russell MR; Liu Q; Fatatis A
Clin Cancer Res; 2010 Oct; 16(20):5002-10. PubMed ID: 20813817
[TBL] [Abstract][Full Text] [Related]
11. Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression.
Verbovšek U; Van Noorden CJ; Lah TT
Semin Cancer Biol; 2015 Dec; 35():71-84. PubMed ID: 26320409
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone.
Kirk PS; Koreckij T; Nguyen HM; Brown LG; Snyder LA; Vessella RL; Corey E
Int J Mol Sci; 2013 May; 14(5):10483-96. PubMed ID: 23698775
[TBL] [Abstract][Full Text] [Related]
13. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
Leung P; Pickarski M; Zhuo Y; Masarachia PJ; Duong LT
Bone; 2011 Oct; 49(4):623-35. PubMed ID: 21718816
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.
Yuan XY; Ren Z; Wu Y; Bougault C; Brizuela L; Magne D; Buchet R; Mebarek S
Bioorg Med Chem; 2019 Mar; 27(6):1034-1042. PubMed ID: 30773420
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
Dorai T; Dutcher JP; Dempster DW; Wiernik PH
Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
[TBL] [Abstract][Full Text] [Related]
19. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.
Podgorski I; Linebaugh BE; Sameni M; Jedeszko C; Bhagat S; Cher ML; Sloane BF
Neoplasia; 2005 Mar; 7(3):207-23. PubMed ID: 15799821
[TBL] [Abstract][Full Text] [Related]
20. An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice.
Panwar P; Xue L; Søe K; Srivastava K; Law S; Delaisse JM; Brömme D
J Bone Miner Res; 2017 Dec; 32(12):2415-2430. PubMed ID: 28745432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
